Member Info for PM2022

A few years back this went from about 3p to 74p in a few weeks. We were priced to go bust before the placing, now fully funded for 2025 and with all the news within the pipeline due.

News due on SPV in the coming weeks, new compound, VAL201 deal seems to be progressing. Val 401 deal and CLX001 news. Further revenue contracts will also come. We should also shortly get further news regarding the merger for 201.

Back then when this was 3p it was also priced to go bust. Now all the news will start to price in so it literally can spike to 20p if the deals conclude as so undervalued at the moment.

2.00 p in the next few weeks post positive SPV news.

Seen a few go up 500% plus this week. Post deal 10p plus.

I'll explain why it matters when the CEO owns 6% and the company is undervalued.

It’s been said that a new SPV could be worth around £10 million. CLX has shown great potential so far, and with the formulation mostly done, the next step is safety testing. If the results are good, it could really boost the valuation.

Right now, CLX isn’t really factored into the price much. A marketing study could easily show the potential and get more attention. FAR did something similar last November, and their share price jumped from 2p to 10p, even though it was in a different sector and situation.

If the valuation stays low, it could bring early offers, but they could turn them down and wait for a better deal after more progress is made.

If both the 201 and 401 deals don’t work out—which I don’t think will happen—Valirx would still be worth something. If CLX keeps making progress and there’s another SPV with at least £4 million valuation for the Inaphea's product lines, another company would probably offer at least £15 million for Valirx, even without 201 and 401.

If 201 and /or 401 do go through, then the share price could still easily hit 5–10p or more. So, even if everything fails, I’m sure they’ve got a Plan C ready to keep things going.

Mark will want a significant return from his investment so I think at this price with so much news due the price will just keep going up. Obviously we could get small dips along the way but the trend should be upwards therefore a great hold.

I will be looking at 5p as a minimum but will derisk slightly along the way.

FYI: Someone that believes in CLX and the progress so far:

Published research: "Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer" Chen, C. H., Liu, Y. H., Eskandari, A., Ghimire, J., Lin, L. C., Fang, Z. S., Wimley, W. C., Ulmschneider, J. P., Suntharalingam, K., Hu, C. M. J. & Ulmschneider, M. B., (2022), Advanced Science. 9, 13 2105506. DOIs: https://doi.org/10.1002/advs.202105506

Review: "Development of membrane-active peptide therapeutics in oncology" Chen, C. H., Zan, B., Ulmschneider, J. P., Wimley, W. C., Lu, T. K. Ulmschneider, M. B., Zhou, L. (2023) Journal of Peptide Science DOIs: https://doi.org/10.1002/psc.3482

What is next Ken Sorenson buys 10% and this will explode even without news?

Not far away from potential SPV news which should give us a nice strong rise.

Then 2 deals that could conclude in the coming weeks/months with further information likely to come regarding the merger.

This should hopefully move past 1p this month.

Because of the anticipated placing before Christmas people have forgotten the excellent start made from the revenue side back In November.

We should get a few more contracts soon so revenue stream should be good this year but the biggest upside is licensing deals and if that gets over the line the market cap will increase a fair amount making cash burn look tiny:

Inaphaea is delighted to confirm the execution of a further contract for the provision of cell-based assays to UK biotech company, Amply Discovery Limited ("Amply"). The multiphase contract, potentially worth over £100,000 over a 8 month period, will evaluate various formulations of Amply's developmental siRNA targets in Inaphaea's Triple Negative Breast Cancer (TNBC) Patient Derived Cells (PDCs) as stand-alone agents and in combination with standard of care drugs. The deal includes an upfront payment to Inaphaea of approximately £31,000 with an additional approximately £21,000 payment on completion of the first phase after 4 months and £10,500 on completion of the remaining in-vitro phase after a further 6 weeks. Successful candidates have the option to be evaluated in-vivo using selected PDCs through one of Inaphaea's partners.

Up 707% in a day.

But if it was for a phase 2b drug it would be worth about 200 million to the market cap. Everything is relative. Still it can add about 10-20 million to our market cap and I would happily take that.

Trellus Health up almost 500%. I never buy on a big spike but it has done the move now in a day. That is what can happen when a stock is due news and is massively underinflated.

The earlier they get the news out the bigger the impact will be due to the cash runway we have at the moment.

Oh and I think the merger news and 201 being the main part of that will attract significant US attention. They will look over at us so I would like to cancel the 10p prediction and make it 20p if 201 completes given the low market cap a few big buys from the US could move it north fast.

Agree but likely not a single big move up. Likely with SPV and name of Nasdaq company further details we go past 1.00p as a minimum in the next 2/3 weeks then if the merger is successful we get to 2/3p as that will basically mean 201 will get signed then once it is signed another 200% as it is not really priced in. Throw in 401 we should hit 10p plus in the coming months. CLX update and 401 if 201 fails and we could get some grant funding along the way.

Plenty of significant news due from different parts of the pipeline making it a great investment at this tiny market cap.Fully funded for 2025 and hopefully some decent lab contracts is expected anyway but will help.

Well he is very confident and maybe Peel knows a thing or two about what is going on.

Once more news starts to flow shortly including SPV news and 201 merger news we should head to 1.50p and then a big rise once an announcement is released if expected it is positive.

We were priced to go bust now fully funded for 2025.

Granger Mark knows about patents so would know about this stuff. Very basic for him.

TRX were chosen over large pharma because they specialise in this field.

All that matters is getting the deal signed.

You lot are clowns.

It will last about 6 months then what???? A placing cannot support the working capital. You can claim all you want about deals etc but it needs a 20/30/40 bagger in a few months and realistically that is not possible even if they did get one.

This will head to admin imo as how can a placing support this.

You fool its burning 8 million a year with a tiny market cap.

Cash burn is far to high and unless the market cap increases massively this will be a struglle to survive.,.

Yes, the sharks are back with all the misinformation.

I wonder why? do they want to eat all the shareholders to load up even more.

We are close to placing price with so much significant news due.

Who said they earn 90k?

Based on what factual information?

Goal is to make the lab profitable but it also helps fastrack Valirx projects.

Was. Until it hits a much higher price again. If it hits its first deal and it has two chances shortly then it will be the first one ever. Therefore could be another 10 bagger.

Sounds like you want the placers to sell for whatever reason.